Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Poxel to Present at Upcoming Investor Conferences


POXEL S.A. (Euronext ? POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that company management will present at two upcoming investor conferences in November:

William Blair Boston Innovation Day
Date:
November 12, 2019
Time: 9:00 am EST
Location: 200 Claredon Street, Boston, MA

Jefferies 2019 London Healthcare Conference
Date:
November 20, 2019
Time: 1:20 pm GMT
Location: Waldorf Hilton, London, UK

The Jefferies 2019 London Healthcare Conference presentation will be live streamed via webcast.

To access the webcast, please visit: http://wsw.com/webcast/jeff123/poxel.pa/. The webcast replay will remain available for 90 days following the live presentation.

About Poxel SA

Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel's first-in-class lead product, targets mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel is conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin's development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 clinical testing and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs targeting metabolic, specialty and rare diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: www.poxelpharma.com.


These press releases may also interest you

at 16:25
Canon U.S.A., Inc., a leader in digital imaging solutions, announced today that they will be hosting a Virtual Press Conference to unveil the company's new professional imaging products and technologies. The Virtual Press Conference, which will be...

at 16:15
QSC announces the opening of QSC Netherlands BV, effective April 1, 2020. Based in Geldermalsen, QSC Netherlands BV will serve as the business development hub for Live Sound & Systems in the Benelux region as well as house QSC's EMEA service repair...

at 16:15
INVO Bioscience, Inc. , a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced financial results...

at 16:15
NTN Buzztime, Inc. , announced it received a letter from the NYSE Regulation stating that it is not in compliance with NYSE American LLC continued listing standards. Specifically, the Company is not in compliance with Section 1003(a)(iii) of the NYSE...

at 16:13
Isos Technology, an Atlassian Platinum and Enterprise Solution Partner, announced today that it received the distinction of "Partner of the Year 2019: Enterprise" from Atlassian, a leading provider of collaboration and productivity software, with...

at 16:12
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") announces that its collaborator, EVQLV, has submitted their first panel of candidate therapeutic antibody sequences,...



News published on 7 november 2019 at 11:50 and distributed by: